Guardant Health is a pioneer in non-invasive cancer diagnostics and the first company to commercialize a comprehensive genomic liquid biopsy.
Transforming cancer care
Our proprietary digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. We have combined decades of scientific research, advances in laboratory technology, and our breakthrough innovation in liquid biopsy to create a test that has already handled tens of thousands of samples.
Tumors evolve, treatment must too
Our current products are just the beginning of what we hope to accomplish, and new uses of our platform are emerging.
Today liquid biopsies are largely a tool for therapy selection for advanced cancers. But some day their utility will cover the entire cancer-care continuum. Liquid biopsies may soon be a tool for early detection, an aid in neoadjuvant and adjuvant therapy, and a non-invasive method for residual disease monitoring and recurrence monitoring.
We know cancer is a dynamic disease and evolves in the face of treatment, and understanding that evolution is critical to developing new treatment plans. We have built a massive database of genomic information about how advanced cancers respond to therapy, which will help us map the paths cancers take when under treatment pressure.
The more detail we add to this map, the better we will understand the disease, and the sooner we can hope to defeat it. We believe this resource can accelerate new drug development and improve the lives of all patients fighting cancer.
Our Team
To achieve our goal of turning cancer into manageable disease, we’ve drawn leadership from diverse disciplines and sectors including genomic sequencing, clinical oncology, digital signal processing, bioinformatics, healthcare reimbursement, laboratory operations, consumer web and mobile applications, and biopharmaceuticals.
Helmy Eltoukhy, PhD
Chief Executive Officer
AmirAli Talasaz, PhD
President & COO
Michael Wiley, JD, CPA
Chief Legal Officer
Rick Lanman, MD
Chief Medical Officer
Derek Bertocci
Chief Financial Officer
Mark Jacobstein
Chief User Engagement Officer
Bill Smith, JD, MPA
Senior Vice President, Intellectual Property
Andy Ament
Vice President, Operations
Jenn Buechel
Vice President, Product
Darya Chudova, PhD
Vice President, Bioinformatics
Morteza Minaee, LP.D
Vice President, Regulatory Affairs
Daniel Simon
Vice President, BioPharma Business Development
Stan Skrzypczak
Vice President, Corporate Development and Reimbursement
Our Advisors
Maurice Stroun, PhD
Professor, University of Geneva
David S Hoon, PhD
Head of Molecular Oncology Research, John Wayne Cancer Institute
Eric Topol, MD
Director, Scripps Translational Science Institute
Razelle Kurzrock, MD
Senior Deputy Director for Clinical Science, UC San Diego Moores Cancer Center
David Gandara, MD
Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center
Ronald W. Davis, PhD
Professor of Biochemistry and Genetics, Stanford School of Medicine
Our Investors




Our Partners
We work with bio-pharmaceutical partners, digital health companies, patient advocacy groups and international distributors to make sure our products provide the greatest benefit. If you are interested in building partnerships to improve care for cancer patients, we want to know.
Our Board
Helmy Eltoukhy, PhD
Chief Executive Officer
AmirAli Talasaz, PhD
President & COO
Samir Kaul
General Partner, Khosla Ventures
Aaref Hilaly
Partner, Sequoia Capital
Ian Clark
Ex-CEO, Genentech